The abstract to be presented at the congress is based on research conducted in collaboration between Oulu University Hospital and Kaiku Health. The research investigates a method of utilizing advanced analytics and machine learning in order to predict the onset and continuity of symptoms in patients receiving immune checkpoint inhibitor treatments. The prediction model was developed by utilizing anonymized aggregated real-world patient-reported datasets collected with Kaiku Health.
The results will be presented at the ESMO Immuno-oncology Congress 2019 in Geneva taking place between 11th and 14th of December. The congress is one of the leading global events for immuno-oncology, organised by the European Society for Medical Oncology. Annually significant scientific research on the field of immuno-oncology is presented at the congress.
Full details of the presentation
“Predicting onset and continuity of patient-reported symptoms in patients undergoing immune checkpoint inhibitor (ICI) therapies using machine learning”
Authors: Sanna Iivanainen (Oulu University Hospital), Jussi Ekström (Kaiku Health), Henri Virtanen (Kaiku Health), Jussi Koivunen (Oulu University Hospital)
Date and time: 12th of December at 12:15 – 13:15 at Poster Display Session
About Kaiku Health
Kaiku Health is a digital health intervention platform classified as a Medical Device in cancer care. Its algorithms screen symptoms, notify care team and provide personalised support for patients. Kaiku Health has modules for over 25 cancer types across different cancer care pathways and is currently in use in over 40 European cancer clinics and hospitals.
